MG
CAPR icon

Michael Gelband’s Capricor Therapeutics CAPR Stock Holding History

Michael Gelband’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,570
Closed -$167K – 1556
2024
Q1 		$167K Buy
+24,570
New +$119K ﹤0.01% 1375
2020
Q3 		– Sell
-14,157
Closed -$65K – 1779
2020
Q2 		$65K Buy
+14,157
New +$61.7K ﹤0.01% 1669

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Michael Gelband's CAPR Position: Q2 2024 in Review

Michael Gelband sold out of Capricor Therapeutics (CAPR) in Q2 2024, closing a stake of 24,570 shares — an estimated $167K sold.

Michael Gelband first reported a position in CAPR in Q2 2020 and held it in 2 quarters. The position peaked at $167K in Q1 2024. 61 funds tracked by Wall St. Rank hold CAPR as of Q2 2024.

  • Michael Gelband reported no remaining Capricor Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Michael Gelband sold 24,570 Capricor Therapeutics shares in Q2 2024, an estimated $167K.
  • Michael Gelband first reported a position in Capricor Therapeutics in Q2 2020 and held it in 2 quarters.
  • Michael Gelband's Capricor Therapeutics position peaked at $167K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.